BPH Microwave Thermotherapy Injuries Serious But Infrequent - FDA Notice
This article was originally published in The Gray Sheet
Executive Summary
Urologix will notify its customers that serious, unexpected yet infrequent, procedure-related injuries could result from use of its microwave thermotherapy treatment systems for benign prostatic hyperplasia (BPH) if certain precautions are not taken.
You may also be interested in...
BPH Thermotherapy Device Competition Heats Up With TherMatrx Entry
TherMatrx is hoping that the design of its TMx-2000 transurethral microwave thermotherapy system to treat benign prostatic hyperplasia - specifically, the absence of a cooling mechanism - will give it an edge over comparable devices on the market.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.